Didi Jasmin

Executive Director of the European School of Haematology (ESH)

As the founding Executive Director of the European School of Haematology (ESH), Didi Jasmin devoted her professional life to the field of lifelong learning in Hematology. 

Didi was also the founding Chairperson of the European Hematology Association’s Education Committee.  During her mandate, the committee launched many educational activities and tools including the European system for CME accreditation in Hematology.

Today, Didi continues to contribute in an advisory position to various organizations in Hematology and other medical specialties.

Didi holds degrees in clinical psychology and neuroscience. 

Delphine Rea, MD, PhD

Hôpital Saint-Louis, Paris, France

Dr. Delphine Rea received her Medical Degree, certification in Clinical Hematology and certification in Hemobiology and Transfusion from the University Paris VI, France and her PhD from the University Paris V, France.

Between 1995 and 2000 she left France in order to complete a post-doctoral fellowship and gain scientific experience abroad. She was first appointed by Princeton University, New Jersey, USA, in order to study p53-based vaccines in murine cancer models in the Molecular Biology Laboratory of Pr Arnold J Levine. Then she worked at the Leiden University Medical Center, Netherlands within the ImmunoHematology Department led by Pr Kies Melief, studying human dendritic cell biology in the setting of a EUNIDI network (European Union Network for Investigation of Dendritic Cell Immunotherapy).

At the end of year 2000, Dr Delphine Rea came back to France and was appointed at Saint-Louis University Hospital, Paris, France, where she still works as a physician specialized in Hematology in the Adult Hematology Department and Therapeutic Apheresis Unit. She also belonged to the INSERM UMRS-1160 Immunology Research Unit in Saint-Louis Hospital, where her interest lied in immune responses towards CML and the role of immunity in treatment-free remission.

Her main clinical and research interest now focuses on malignant myeloid disorders and she is responsible for the Chronic Myeloid Leukemia clinical care and research program. She has been the principal investigator or investigator of many academic- or industry-sponsored clinical trials dedicated to CML, including pivotal studies that have led to the approval of tyrosine kinase inhibitors or treatment-free remission studies.

She belongs to the board of directors of the French cooperative group of CML (Fi-LMC), contributes to the CML project of the European LeukemiaNet, to the organization committee of European School of Haematology (ESH) iCMLf annual conference, to the Society of Hematologic Oncology (SOHO) annual meeting education committee and to the scientific advisory board of iCMLf.

Katia Pagnano MD,PhD

Hematologist and Researcher of the Hematology Division of the Hematology and Hemotherapy Center at the University of Campinas, Campinas, SP, Brazil. (since 1996).

Professor of Medicine, Hematology, at the Pontifical Catholic University of Campinas (since 2021).

Dr Pagnano has previously worked as MD at the Faculty of Medicine-University of Campinas (UNICAMP), Campinas, SP, Brazil. (1991) She did her residency and fellowship training in Hematology, Hemotherapy and Bone Marrow Transplantation at Hospital das Clínicas at UNICAMP (1992-1995) and also undertook a split fellowship at the University of Pennsylvania (Philadelphia,USA) in Dr. Gewirtz lab (1998). 

Dr Pagnano has a PhD in Internal Medicine at UNICAMP (2002).  

Dr. Pagnano’s expertise is in treating patients with hematologic malignancies, in particular CML, myeloproliferative disorders (MPN) and AML.  She has participated in Brazilian CML, AML and MPN guidelines  and in the CML Latin America Leukemia Net (LALNET) TFR recommendations. She is a member of the CML Committee from the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) and the President of the Brazilian CML Working Group.

She has been a member of the iCMLf Advisory Board since 1991 and has previously undertook the iCMLf's iClimb for Cure in 2019 - Kilimanjaro. 

Dr Pagnano has participated in several clinical trials, focusing on the treatment of chronic myeloid leukemia, acute myeloid leukemia and lymphomas. She has published in peer-reviewed journals.